Tuesday, October 15, 2013

Losartan drug ingredients





Losartan ( Cozaar ) ( English name : Losartan; Alias: Cozaar Losartan , Losartan ) Method : 1 - butyl-4 - chloro- 5 - (hydroxymethyl) imidazole and sodium methoxide in methanol the reaction solution was stirred , and then the resulting sodium salt and 4' - bromomethyl-2 - cyano- biphenyl in dimethyl formamide was stirred , the ether of the compound obtained , and then sodium azide and ammonium chloride -containing dimethyl formamide reaction, the acid hydrolysis of losartan . Purpose: Cozaar first listed in 1994 , is now in 93 countries have been approved for use for the treatment of hypertension . Oral non-peptide angiotensin Ⅱ receptor antagonist. Mainly used for essential hypertension . Cozaar is the first angiotensin Ⅱ receptor antagonist (AIIA) classes of antihypertensive drugs . Properties: light yellow solid , mp 183.5 ~ 184.5 ℃.
Pharmaceutical ingredients : endogenous renin - angiotensin system (RAS) activation of renin release by the kidneys . Renin from the liver can break down a protein called angiotensinogen , angiotensin decomposed product is I. Although angiotensin I itself has no biological activity, but it is a precursor of angiotensin II , and angiotensin II on vascular , cardiac and other body tissue with a series of biological activity. AIIA drugs such as Cozaar can block the angiotensin receptor (AT1), to avoid binding to receptors of angiotensin II , and ultimately achieve the purpose of preventing vasoconstriction .
Cozaar once a day , usually a dose of 50mg. Similar products Cozaar and Hyzaar is a small dose of diuretic ( hydrochlorothiazide ) combinations , also used to treat high blood pressure. Cozaar treatment alone can not properly control blood pressure in patients can try to use Hyzaar ( losartan 50mg / Hydrochlorothiazide 12.5mg) treatment.
Compared with other anti- hypertensive drugs , Cozaar and Hyzaar main advantage is its well tolerated , side effects is low.


More about:Losartan manufacturer
From:Natural herbal extracts

No comments:

Post a Comment